Prostate Cancer News
In a study, men who underwent high-intensity focused ultrasound partial gland ablation for prostate cancer had excellent preservation of potency and continence.
Localized prostate cancer is thought to metastasize by tapping into a developmental program used by its embryonic ancestors.
Darolutamide also improved secondary endpoints, including the time to pain progression, cytotoxic chemotherapy, and first symptomatic skeletal event.
In a study, only androgen deprivation therapy with oral antiandrogens were associated with an increased risk for dementia and Alzheimer disease.
By 2016, radical prostatectomy use nearly equaled radiation therapy use for high-risk prostate cancer.
Deferring radical prostatectomy for intermediate- and high-risk prostate cancer for several months does not increase the risk for adverse oncologic findings.
Using a blood sample, the test is able to analyze more than 300 cancer-associated genes for alterations.
The model, based on routinely collected clinical characteristics, provides information that can enhance discussions between health care professionals and patients on active surveillance intensity.
Given that the findings do not show major differences between care options in prostate cancer, cost probably shouldn’t be a major factor driving decision making.
Metastatic prostate cancer (PCa) at diagnosis and recurrent metastatic PCa after initial treatment may be distinct biological entities with different survival trajectories, according to investigators.
In a study of patients undergoing transperineal prostate biopsy, the detection rate of clinically significant prostate cancer did not differ significantly between targeted biopsy (TB) with fewer systematic biopsy (SB) cores and TB with SB of the whole prostate.
The latest analyses found 5-year overall survival benefits across low-, intermediate-, and high-risk subgroups of men with chemotherapy-naïve metastatic castration-resistant prostate cancer.
The authors of a new review discuss priorities, adjustments, and tailored approaches to prostate cancer management during the COVID-19 pandemic.
Postponing transperineal prostate biopsies in men with suspicious MRI-detected lesions had no effect on biopsy findings, which could have important implications during the COVID-19 pandemic.
The new stratification model may aid treatment decision-making for men with “favorable,” high-risk, or “very” high-risk prostate cancer.
Copy number loss of 17q22 was associated with enzalutamide resistance and shorter overall survival among men with metastatic castration-resistant prostate cancer.
Radiation therapy for higher-risk prostate cancer can be delayed for up to 6 months following initiation of hormonal therapy without incurring a greater mortality risk, a finding that has implications for patient care during the COVID-19 pandemic.
The social media platform can be useful as an education tool for oncologists to stay up to date on new research in oncology — but physicians still need to be mindful of the information sources.
Allowing an approximately 24-month recovery period after prostate surgery before giving radiation therapy may be optimal for preserving erectile function provided oncologic control is not compromised, according to investigators.
It remains important to interrogate how structural discrimination influences the collection of patient-reported outcomes.